MARTINSRIED, Germany, March 20, 2007 (PRIME NEWSWIRE) (PRIMEZONE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment:TecDAX) today announced that its business unit AbD Serotec has significantly expanded its license agreement with MRC Technology (MRCT), the technology transfer arm of Great Britain’s Medical Research Council (MRC). The agreement, which provides AbD Serotec with access to a broad range of hybridoma cell lines as a source of research antibodies, is extended for a further five years, and includes additional products which will be implemented in AbD Serotec’s offering. Financial details of the agreement were not disclosed.
